Description
PrymaLab · Research use only
Tirzepatide 5mg
The smallest tirzepatide fill: 5 mg, about 1.04 µmol of freeze-dried peptide
Tirzepatide is a 39-residue synthetic peptide, acylated at lysine 20 with a C20 fatty diacid, that acts on both the GIP and the GLP-1 receptor. The 5 mg vial is the smallest of ten fills: white freeze-dried powder made as its own lot, about 1.04 µmol of peptide. Most published work on the compound concerns how it divides its activity between the two receptors.
Specifications
| Property | Value |
|---|---|
| Compound | Tirzepatide LY3298176; GIP/GLP-1 receptor dual agonist |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Theoretical mass | 4813.5 Da |
| Sequence / structure | H-Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(2×AEEA-γGlu-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH₂ (39 residues; Aib2 and Aib13; Lys20 acylated with eicosanedioic acid via γ-Glu and two AEEA spacers; C-terminal amide) |
| Label claim | 5 mg/vial |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Lot certificate | Results for the lot now shipping are in the certificate panel on this page |
| Safety data sheet | PL-SDS-173 |
Other fills
This is the 5 mg fill. The Tirzepatide 10mg page is the main listing for this compound, with the full research summary and every fill side by side. Other fills: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg.
What the research covers
Willard and colleagues calculated receptor occupancy at clinically relevant drug levels and found that tirzepatide engaged the GIP receptor more than the GLP-1 receptor, a pattern they called imbalanced1. At the GIP receptor its signalling matched that of native GIP1. Those are results from cell assays and modelling, not from studies of this material. The Tirzepatide 10 mg main listing carries the rest of the literature, from receptor structure to phase 3 trials.
The Retatrutide vs Tirzepatide guide covers the literature in more depth.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. The results for the lot now shipping are in the certificate panel on this page, and the certificate number, key and QR code can be checked on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Is the 5 mg vial held to the same standard as the larger fills?
Yes. It is the same compound, released against the same purity specification of 99.0% or higher by RP-HPLC, with identity confirmed by LC-MS. As a separate lot it has its own lot number and certificate.
What does 5 mg come to in molar terms?
About 1.04 µmol, from the theoretical mass of 4813.5 Da on the certificate. Dissolved to 1 mL that is close to a 1 mM stock. Residual water in the powder, which the certificate reports, puts the true figure slightly lower.
References
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17). DOI · PubMed
Research use only
For laboratory research use only. Tirzepatide 5mg is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.